A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

Cancer Care Wollongong, Wollongong, New South Wales

China

Shanghai East Hospital, Shanghai, Shanghai Municipality